Chinese scientist faces probe after girl, 6, dies ‘following experimental gene therapy’

Lead

A six-year-old girl died in March last year after receiving experimental gene-editing therapy designed to correct a neurodevelopmental genetic mutation. The case has prompted an investigation by Shanghai Jiao Tong University into the lead scientist, Qiu Zilong, a neuroscientist at the university’s brain centre.

Coverage comparison

The South China Morning Post reports that the girl, identified only as Mei, died days after the therapy was administered. The treatment involved infusing trillions of viruses carrying the recipe for a base editor into her spinal fluid, according to a joint investigation by Retraction Watch and the journal Science. Her parents said she suffered a fatal immune reaction linked to the treatment.

Xinhua Hospital, affiliated with the university, paid a fine of approximately 24,000 yuan (US$3,500) to local health authorities last September, according to the same reports. Qiu faced no public sanctions at the time. The hospital’s role and the size of the fine have been noted in the coverage.

Key claims

• A six-year-old girl died after receiving experimental gene-editing therapy. The therapy was designed to correct a neurodevelopmental genetic mutation. — as reported by the South China Morning Post.
• The girl suffered a fatal immune reaction linked to the treatment, according to her parents and the joint investigation by Retraction Watch and Science, as reported by the South China Morning Post.
• The trial was led by Qiu Zilong, a neuroscientist at Shanghai Jiao Tong University, as reported by the South China Morning Post.
• Xinhua Hospital paid a fine to local health authorities, as reported by the South China Morning Post.
• Scientists have described the death as a tragedy highlighting the need for improved trial safeguards, the South China Morning Post reported.
• Some in the biotechnology industry fear a regulatory backlash that could curtail the flexibility scientists have in initiating clinical trials — a factor seen as key to China’s competitive edge in frontier treatments, according to the South China Morning Post.

Perspectives

Biotechnology industry — Wang Haoran, chief executive of Neoland Biosciences, told the South China Morning Post that he hopes the tragedy does not have a lasting negative impact on China’s investigator-initiated clinical research system, but acknowledged a real risk of regulatory backlash. He said China’s rapid advances in frontier areas have partly come from the flexibility of early clinical exploration, which has increased urgency in U.S. and European biotech industries. He also said the case appears to reveal serious failures in risk assessment, transparency, and institutional oversight, and that stronger safeguards are needed, especially for first-in-human gene-editing treatments involving children.